| 2025-08-14 |
详情>>
内部人交易：
Topsoe Jakob Haldor等共交易8笔
|
| 2025-07-31 |
详情>>
股本变动：
变动后总股本6029.27万股
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益0.73美元,归母净利润4469.20万美元,同比去年增长145.74%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.86美元,归母净利润-5289.2万美元,同比去年增长-6.17%
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-3.24美元,归母净利润-1.96亿美元,同比去年增长20.54%
|
| 2025-03-06 |
详情>>
业绩披露：
2022年年报每股收益-5.32美元,归母净利润-2.21亿美元,同比去年增长-33.87%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.63美元,归母净利润-1.59亿美元,同比去年增长14.31%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-1.62美元,归母净利润-9771.8万美元,同比去年增长21.02%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.83美元,归母净利润-4981.6万美元,同比去年增长16.01%
|
| 2024-05-08 |
详情>>
业绩披露：
2023年一季报每股收益-1.33美元,归母净利润-5930.9万美元,同比去年增长-14.29%
|
| 2024-04-26 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to serve until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.
3.To approve an amendment to our amended and restated certificate of incorporation to limit the liability of certain officers as permitted by Delaware law.
4.To approve a stock option exchange program for employees (excluding our chief executive officer and non-employee directors), as described in this proxy statement.
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-4.71美元,归母净利润-2.46亿美元,同比去年增长-11.45%
|
| 2023-12-06 |
复牌提示：
2023-12-05 16:00:11 停牌，复牌日期 2023-12-05 16:30:00
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.73美元,归母净利润-1.86亿美元,同比去年增长-10.2%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-2.76美元,归母净利润-1.24亿美元,同比去年增长-11.99%
|
| 2023-04-27 |
股东大会：
将于2023-06-23召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.
3.To approve the amendment and restatement of the IGM Biosciences, Inc. Amended and Restated 2018 Omnibus Incentive Plan (the 2018 Plan), which increases the number of shares authorized for issuance thereunder by 2,160,000 shares.
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2023-03-30 |
财报披露：
美东时间 2023-03-30 盘后发布财报
|
| 2022-04-27 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to serve until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.
3.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-24召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to serve until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.
3.To approve an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of our non-voting common stock from 6,431,208 to 200,000,000, with a corresponding increase to the total number of authorized shares of our Common Stock.
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2020-07-06 |
股东大会：
将于2020-07-30召开股东大会
会议内容 ▼▲
- 1.To approve the amendment and restatement of our 2019 Employee Stock Purchase Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase under such plan includes both voting and non-voting shares of our common stock.
2.To approve the amendment and restatement of our Amended and Restated 2018 Omnibus Incentive Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase under such plan includes both voting and non-voting shares of our common stock.
3.To transact such other business as may properly come before the Special Meeting or any adjournments or postponements thereof.
|
| 2020-04-21 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to serve until the 2023 annual meeting of stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.
3.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|